EDITORIAL SECTION

Sagent Pharmaceuticals Sagent a leading provider of generic and specialty pharmaceuticals today announced that Zyogreen indocyanine green injection the first and only FDAapproved readytouse

Envisagenics today announced a multiyear research collaboration and option agreement with Boehringer Ingelheim to validate selected tumorspecific targets for the development of firstinclass precision therapies

Eli Lilly and Company NYSE LLY broke ground today in Houston Texas one of ten US manufacturing sites and fifth location to produce domestic active pharmaceutical ingredients API

Iambic a clinicalstage life science and technology company developing novel medicines using its AIdriven platform today unveiled Enchant v the next generation of its multimodal transformer model built

The US Food and Drug Administration FDA has granted Orphan Drug Designation to Kedrion Biopharmas QIVIGY immune globulin intravenous human solution for the potential treatment of Stiff Person Syndrome SPS

Pretzel Therapeutics has received Fast Track Designation from the US Food and Drug Administration FDA for PX an investigational treatment for POLGmediated primary mitochondrial disorders also known as POLG disease

BoomRay Pharmaceuticals has entered into an exclusive global licensing agreement with Novartis Pharma for an undisclosed preclinical radioligand therapy RLT asset

AbbVie and Iambic have entered into a multiyear collaboration to accelerate the discovery and development of smallmolecule therapies with potential firstinclass and bestinclass profiles across immunology neuroscience and oncology

The US Food and Drug Administration FDA has granted full approval to Eli Lilly and Companys Inluriyo imlunestrant in combination with Verzenio abemaciclib for adults with estrogen receptorpositive ER

Amneal Pharmaceuticals has received approval from the US Food and Drug Administration FDA for its lanreotide injection mg mL supplied in a sterile singledose prefilled syringe